lymphat
system
first
recognis
gaspar
aselli
anatomi
lymphat
system
almost
complet
characteris
earli
nineteenth
centuri
howev
knowledg
blood
circul
continu
grow
rapidli
last
centuri
two
differ
theori
propos
favour
origin
lymphat
vessel
firstli
centrifug
theori
embryolog
origin
lymphat
describ
earli
twentieth
centuri
sabin
later
lewi
postul
lymphat
endotheli
cell
lec
deriv
venou
endothelium
later
centripet
theori
lymphat
develop
propos
huntington
mcclure
describ
develop
lymphat
system
begin
lymphangioblast
mesenchym
progenitor
cell
aris
independ
vein
venou
connect
lymphat
system
happen
later
develop
lymphat
vessel
embryo
origin
midgest
develop
cardiovascular
system
fulli
establish
function
dual
origin
lymphat
vessel
embryon
vein
mesenchym
lymphangioblast
also
propos
recent
studi
provid
strong
support
venou
origin
lymphat
vessel
recent
discoveri
variou
molecular
marker
allow
indepth
research
lymphat
system
role
health
diseas
lymphat
system
recent
elucid
play
activ
role
cancer
metastasi
knowledg
activ
process
involv
lymphat
metastasi
provid
novel
treatment
target
variou
malign
lymphat
system
consist
lymphat
vessel
lymph
node
spleen
thymu
peyer
patch
tonsil
play
import
role
immun
surveil
respons
lymphat
system
serv
bodi
second
vascular
system
vertebr
function
codepend
cardiovascular
system
lymphat
system
compris
singl
irrevers
openend
transit
network
without
princip
drive
forc
consist
five
main
type
conduit
includ
capillari
collect
vessel
lymph
node
trunk
duct
lymphat
system
origin
dermi
initi
lymphat
vessel
blindend
lymphat
capillari
nearli
equival
size
less
abund
regular
capillari
lymphat
capillari
consist
singl
layer
thinwal
nonfenestr
lymphat
endotheli
cell
lec
alik
blood
capillari
lec
contrari
blood
vessel
poorli
develop
basement
membran
lack
tight
junction
adher
junction
porou
capillari
act
gateway
larg
particl
cell
interstiti
fluid
particl
larg
nm
diamet
extravas
interstiti
space
get
phagocytos
macrophag
ultim
pass
lymph
node
lymphat
capillari
endotheli
cell
affix
extracellular
matrix
elast
anchor
filament
check
vessel
collaps
high
interstiti
pressur
initi
lymphat
posit
pressur
gradient
distend
creat
open
loos
anchor
endotheli
cell
let
entri
lymph
proteinrich
exud
blood
capillari
initi
lymphat
vessel
overli
endotheli
contact
prevent
fluid
reflux
back
interstiti
space
collect
lymph
lymphat
capillari
transport
system
converg
lymphat
vessel
progress
larger
size
filter
lymph
node
bacteria
particul
matter
remov
final
goe
back
blood
circul
lymph
receiv
initi
capillari
lymphat
deeper
collect
vessel
contain
valv
maintain
unidirect
flow
lymph
collect
vessel
basement
membran
surround
smooth
muscl
cell
intrins
contractil
activ
combin
contract
surround
skelet
muscl
arteri
pulsat
propel
lymph
lymph
node
collect
lymphat
vessel
unit
lymphat
trunk
lymph
final
return
venou
circul
via
thorac
duct
left
subclavian
vein
flow
lymph
toward
circulatori
system
support
increas
interstiti
pressur
well
contract
lymphat
vessel
roughli
l
lymphat
fluid
enter
cardiovascular
system
day
key
function
lymphat
system
mainten
normal
tissu
fluid
balanc
absorpt
lipid
fatsolubl
vitamin
intestin
magnet
transport
immun
cell
lymphat
transport
antigenpres
cell
well
antigen
interstitium
peripher
tissu
drain
lymph
node
initi
immun
respons
via
b
tcell
lymph
node
tissu
fluid
balanc
maintain
restor
interstiti
fluid
cardiovascular
system
although
capillari
low
permeabl
protein
molecul
well
macromolecul
bacteria
accumul
interstitium
due
accumul
larg
molecul
interstitium
signific
tissu
oedema
would
result
lymphat
system
offer
mechan
larg
molecul
reenter
blood
circul
lymphat
system
site
mani
diseas
metastiti
tuberculosi
tb
cancer
filariasi
due
peculiar
natur
anatomi
lymphat
system
localis
drug
lymphat
particularli
difficult
achiev
lymphat
system
activ
role
cancer
metastasi
although
mani
cancer
may
treat
surgic
resect
microscop
diseas
may
remain
lead
locoregion
recurr
convent
system
chemotherapi
prove
effect
deliv
drug
lymphat
system
without
doselimit
toxic
lymphat
system
function
clearanc
particul
matter
interstitium
follow
present
lymph
node
creat
interest
develop
microparticul
system
target
region
lymph
node
molecul
composit
import
determin
uptak
lymphat
retent
within
lymph
node
colloid
materi
exampl
liposom
activ
carbon
particl
emuls
lipid
polymer
particul
highli
taken
lymphat
nowaday
substanc
emerg
potenti
carrier
lymphat
drug
target
vast
major
drug
follow
oral
administr
absorb
directli
portal
blood
number
lipophil
molecul
may
get
access
system
circul
via
lymphat
pathway
intestin
lymphat
transport
lipophil
molecul
signific
present
benefit
number
situat
total
system
bioavail
lipophil
molecul
may
increas
hepat
firstpass
metabol
may
reduc
intestin
lymphat
absorpt
target
immunomodulatori
agent
cytotox
agent
drug
use
treatment
human
immunodefici
viru
hiv
lymphat
system
potenti
maximis
therapeut
benefit
minimis
system
exposur
follow
associ
drug
chylomicron
intestin
lymphat
transport
may
alter
pharmacokinet
pharmacodynam
properti
drug
lymphat
system
also
act
primari
system
transport
pathway
b
tlymphocyt
well
main
rout
metastat
spread
number
solid
tumour
therefor
lymphat
absorpt
immunomodulatori
anticanc
compound
may
effect
presenc
wide
amount
hivsuscept
immun
cell
lymphoid
organ
make
antiretrovir
drug
target
site
tremend
interest
hiv
therapi
strategi
compris
target
nanosystem
immun
cell
popul
particularli
macrophag
also
evid
suggest
lymph
lymphoid
tissu
particular
gutassoci
lymphoid
tissu
play
major
role
develop
hiv
antivir
target
acquir
immunodefici
syndrom
aid
may
therefor
effect
absorb
via
intestin
lymphat
virus
like
hepat
b
morbilliviru
also
replic
gutassoci
lymphoid
tissu
close
relat
canin
distemp
viru
includ
sever
acut
respiratori
syndrom
sar
associ
coronaviru
may
also
spread
via
lymphat
network
chronic
persist
hepat
c
believ
result
uptak
system
lymphocyt
sequestr
lymph
target
drug
lymphat
system
tough
challeng
task
total
depend
upon
intric
physiolog
lymphat
system
target
facilit
direct
contact
drug
specif
site
decreas
dose
drug
minimis
side
effect
caus
current
nanocarri
encourag
lymphat
target
still
challeng
locat
drug
bioactiv
specif
site
maintain
desir
action
cross
physiolog
barrier
hurdl
could
overcom
use
modifi
nanosystem
achiev
surfac
engin
phenomena
lymph
node
dissemin
primari
caus
spread
major
solid
cancer
regard
cancer
metastasi
statu
lymph
node
major
determin
patient
diagnosi
import
factor
determin
appropri
care
patient
correct
lymph
node
stage
patient
surviv
shown
improv
therapeut
intervent
treat
metastat
cancer
lymph
node
either
surgeri
local
radiat
therapi
viraemia
earli
indic
primari
infect
hiv
follow
specif
hiv
immun
respons
dramat
declin
viru
plasma
long
hiv
viru
found
blood
hiv
found
high
level
mononuclear
cell
locat
lymph
node
viral
replic
lymph
node
report
higher
peripher
blood
mononuclear
cell
standard
oral
intraven
drug
deliveri
lymph
node
mononuclear
cell
difficult
even
highli
activ
antiretrovir
therapi
haart
reduc
plasma
viral
load
hivinfect
patient
activ
viru
still
isol
lymph
node
even
month
haart
therapi
lymph
node
key
element
life
cycl
sever
parasit
organ
includ
filaria
lymphat
vessel
lymph
node
infect
patient
carri
adult
worm
adult
filaria
obstruct
lymphat
drainag
result
swell
extrem
distal
infect
lymph
node
symptom
swollen
limb
patient
filari
diseas
term
elephantiasi
erad
adult
worm
lymph
node
frequent
possibl
commonli
much
extend
cours
medic
therapi
requir
success
new
method
cure
anthrax
becom
burn
interest
follow
recent
outburst
anthrax
infect
death
usa
result
terror
anthrax
infect
endospor
bacillu
anthraci
gain
access
bodi
phagocytos
macrophag
carri
region
lymph
node
endospor
germin
insid
macrophag
becom
veget
bacteria
accord
one
literatur
comput
tomographi
chest
perform
eight
patient
infect
inhal
anthrax
mediastin
lymphadenopathi
found
seven
eight
patient
anoth
case
report
patient
anthrax
bacillu
shown
rapidli
sterilis
within
blood
stream
initi
antibiot
therapi
howev
viabl
anthrax
bacteria
still
present
postmortem
mediastin
lymph
node
specimen
treatment
control
diseas
hard
accomplish
limit
access
drug
mediastin
node
use
common
pathway
drug
deliveri
also
anatom
locat
mediastin
node
repres
difficult
target
extern
beam
irradi
newer
method
target
antituberculosi
drug
lymph
node
could
possibl
decreas
amount
time
drug
therapi
tb
requir
lengthi
treatment
minimum
approxim
month
probabl
difficulti
deliv
drug
tubercular
lesion
tb
infect
caus
mycobacteria
invad
grow
chiefli
phagocyt
cell
lymph
node
tb
common
form
extrapulmonari
tb
rate
approxim
frequent
found
spread
lung
lymph
node
one
studi
total
tb
lymph
node
involv
found
intrathorac
lymph
node
cervic
lymph
node
axillari
lymph
node
passiv
target
involv
transport
carrier
leaki
tumour
vasculatur
tumour
interstitium
cell
convect
passiv
diffus
nanocarri
drug
accumul
target
site
enhanc
permeat
retent
epr
effect
epr
effect
promin
mainli
cancer
target
moreov
epr
effect
pertin
fastgrow
solid
tumour
epr
effect
posit
nanocarri
escap
immun
surveil
circul
long
period
high
local
concentr
drugload
nanocarri
attain
target
site
exampl
higher
normal
tissu
within
day
howev
exist
limit
passiv
target
tumour
first
degre
tumour
vascularis
angiogenesi
import
passiv
target
nanocarri
second
due
poor
lymphat
drainag
tumour
interstiti
fluid
pressur
increas
correl
nanocarri
size
relationship
epr
effect
larger
longcircul
nanocarri
nm
retain
tumour
wherea
smaller
molecul
easili
diffus
activ
target
base
upon
attach
target
ligand
surfac
nanocarri
appropri
receptor
bind
express
target
site
ligand
particularli
bind
receptor
overexpress
particular
diseas
cell
tumour
vasculatur
express
normal
cell
addit
target
receptor
present
uniformli
target
cell
target
ligand
either
monoclon
antibodi
mab
antibodi
fragment
nonantibodi
ligand
peptid
also
term
ligandtarget
therapeut
target
approach
lymphat
target
shown
fig
emuls
probabl
wellknown
particul
carrier
compar
histori
research
wide
use
carrier
lymph
target
hashida
et
al
demonstr
inject
waterinoil
wo
oilinwat
ow
emuls
favour
lymphat
transport
mitomycin
c
via
intraperiton
intramuscular
rout
uptak
region
lymphat
report
order
ow
wo
aqueou
solut
nanoparticleinoil
emuls
system
contain
antifilari
drug
gelatin
nanoparticl
studi
enhanc
lymphat
target
pirarubicin
lipiodol
emuls
formul
develop
treat
gastric
cancer
metastat
lymph
node
endoscop
inject
emuls
drug
retain
day
inject
site
region
lymph
node
hauss
et
al
studi
explor
lymphotrop
potenti
emuls
selfemulsifi
drug
deliveri
system
sedd
investig
effect
rang
lipidbas
formul
bioavail
lymphat
transport
ontazolast
follow
oral
administr
consciou
rat
found
lipid
formul
increas
bioavail
ontazolast
compar
control
suspens
sedd
promot
rapid
absorpt
maximum
lymphat
transport
found
emuls
lymphat
deliveri
drugencapsul
liposom
formul
investig
extens
past
decad
liposom
possess
ideal
featur
deliv
therapeut
agent
lymph
node
base
size
prevent
direct
absorpt
blood
larg
amount
drug
therapeut
agent
liposom
carri
biocompat
util
liposom
carrier
lymphat
deliveri
first
investig
segal
et
al
oral
administ
drugincorpor
liposom
enter
system
circul
via
portal
vein
intestin
lymphat
drug
enter
intestin
lymphat
intestin
lumen
avoid
liver
firstpass
metabol
first
migrat
lymphat
vessel
drain
lymph
node
enter
system
circul
lymphat
uptak
carrier
via
intestin
rout
increas
bioavail
number
drug
oral
deliveri
drugencapsul
liposom
formul
intestin
absorb
stabil
primari
formul
concern
ling
et
al
evalu
oral
deliveri
poorli
bioavail
hydrophil
drug
cefotaxim
three
differ
form
liposom
formul
aqueousfre
drug
physic
mixtur
drug
empti
liposom
liposom
formul
drug
turn
exhibit
increas
oral
bioavail
compar
aqueou
dosag
increas
physic
mixtur
also
account
liposom
formul
lead
signific
enhanc
lymphat
localis
drug
rel
two
formul
result
liposom
system
emerg
use
carrier
poorli
bioavail
hydrophil
drug
promot
lymphat
transport
intestin
lymph
well
system
bioavail
convent
liposom
formul
contain
anticanc
drug
incorpor
intraven
infus
treat
variou
type
cancer
doxil
chemotherapeut
formul
pegyl
liposom
doxorubicin
wide
use
firstlin
therapi
aidsrel
kaposi
sarcoma
breast
cancer
ovarian
cancer
solid
tumour
liposom
deliveri
anticanc
drug
actinomycin
via
intratesticular
inject
shown
greater
concentr
drug
local
lymph
node
furthermor
studi
hirnl
et
al
found
liposom
better
carrier
intralymphat
deliv
drug
contrast
bleomycin
emuls
system
liposom
chemotherapi
prefer
mainli
reduc
side
effect
compar
standard
therapi
improv
inhibit
anticanc
drug
enzymat
digest
system
circul
effect
chemotherapi
pulmonari
rout
could
overcom
variou
lacuna
associ
system
chemotherapi
like
seriou
nontarget
toxic
poor
drug
penetr
lymphat
vessel
surround
lymph
node
firstpass
clearanc
concentr
drug
lung
drain
lymphat
case
oral
deliveri
latim
et
al
develop
liposom
paclitaxel
vitamin
e
analogu
acet
acid
aerosol
formul
treat
murin
mammari
tumour
metastas
similarli
lawson
et
al
perform
compar
studi
antiprolif
efficaci
encapsul
dilauroylphosphatidylcholin
liposom
deliveri
combin
therapi
metastat
murin
mammari
tumour
model
liposomeencapsul
individu
well
combin
treatment
deliv
via
aerosol
cure
metastas
lung
surround
lymph
node
anim
treat
combin
therapi
found
less
prolif
cell
compar
anim
treat
alon
immunostain
vivo
anticanc
efficaci
studi
demonstr
combin
treatment
greatli
hinder
tumour
progress
compar
treatment
alon
lead
prolong
surviv
rate
high
level
drug
could
target
lymph
node
contain
tb
use
liposom
antituberculosi
drug
therapi
deep
lung
lymphat
drainag
could
also
visualis
use
radioact
markerincorpor
liposom
addit
botelho
et
al
deliv
aerosolis
nanoradioliposom
formul
wild
boar
observ
deep
lung
lymphat
network
surround
lymph
node
also
techniqu
offer
new
inform
complic
structur
lymphat
network
emerg
new
noninvas
molecular
imag
techniqu
diagnosi
earli
dissemin
lung
cancer
compar
convent
comput
tomographi
solid
lipid
nanoparticl
sln
could
good
formul
strategi
incorpor
drug
poor
oral
bioavail
due
low
solubl
gi
tract
presystem
hepat
metabol
firstpass
effect
permit
transport
system
circul
intestin
lymphat
bargoni
et
al
perform
variou
studi
absorpt
distribut
sln
duoden
administr
one
studi
acidlabel
drugfre
sln
deliv
duoden
lumen
fed
rat
transmiss
electron
microscopi
photon
correl
spectroscopi
result
lymph
blood
sampl
verifi
transmucos
transport
sln
later
studi
tobramycinload
sln
duoden
administr
improv
drug
absorpt
bioavail
ascrib
mostli
favour
transmucos
transport
sln
lymph
compar
blood
group
conduct
studi
use
idarubicinload
sln
administ
via
duoden
rout
rather
intraven
rout
observ
enhanc
drug
bioavail
reddi
et
al
prepar
etoposideload
tripalmitin
etpl
sln
radiolabel
administ
etpl
nanoparticl
subcutan
intraperiton
intraven
mice
bear
dalton
lymphoma
tumour
h
subcutan
administr
gamma
scintigraphi
radioact
measur
show
etpl
sln
reveal
clearli
higher
degre
tumour
uptak
given
via
subcutan
rout
higher
intraperiton
intraven
rout
respect
reduc
accumul
reticuloendotheli
system
organ
target
therapi
great
potenti
small
cell
lung
cancer
consid
intrathorac
lymph
node
metastasi
occur
approxim
limit
stage
patient
nearli
extens
stage
patient
consid
case
nonsmal
cell
lung
cancer
extens
rate
metastasi
lymphat
seen
greater
stage
iv
patient
videira
et
al
compar
biodistribut
inhal
lhexamethylpropyleneamin
oxim
hmpao
radiolabel
sln
free
tracer
administ
rout
gamma
scintigraph
result
specifi
radiolabel
sln
primarili
clear
lung
via
lymphat
nanocapsul
tend
promis
approach
lymphat
target
possibl
attain
distinct
qualiti
easi
manufactur
process
nanocapsul
coat
hydrophob
polym
could
easili
captur
lymphat
cell
bodi
administ
hydrophob
particl
gener
recognis
foreign
substanc
lymphat
target
abil
poli
isobutylcyanoacryl
nanocapsul
encapsul
stearic
acid
upon
intramuscular
administr
evalu
compar
three
convent
colloid
carrier
vivo
studi
rat
prove
poli
isobutylcyanoacryl
nanocapsul
retain
right
iliac
region
lymph
node
comparison
colloid
carrier
follow
intramuscular
administr
dextran
natur
polysaccharid
use
carrier
rang
drug
molecul
due
outstand
biocompat
bhatnagar
et
al
synthesis
cyclosporin
aload
dextran
acet
particl
label
particl
gradual
distribut
cyclosporin
lymph
node
follow
subcutan
inject
footpad
rat
dextran
averag
molecular
weight
kda
conjug
lymphotrop
deliveri
system
mitomycin
c
studi
report
intramuscular
inject
mice
mitomycin
conjug
retain
longer
period
region
lymph
node
nearli
h
free
mitomycin
quickli
clear
hyaluronan
also
call
hyaluron
acid
natur
biocompat
polym
follow
lymphat
drainag
interstiti
space
cai
et
al
demonstr
novel
intralymphat
drug
deliveri
method
synthesis
acid
conjug
breast
cancer
treatment
follow
subcutan
inject
upper
mammari
fat
pad
femal
rat
carrier
localis
region
nodal
tissu
compar
standard
cisplatin
formul
poli
lactidecoglycolid
synthet
polym
use
prepar
biodegrad
nanospher
account
deliv
drug
diagnost
agent
lymphat
system
similarli
nanospher
coat
block
copolym
poloxam
poloxamin
radiolabel
use
trace
nanoparticl
vivo
upon
sc
inject
region
lymph
node
show
maximum
uptak
administ
dose
dunn
et
al
synthesis
conjug
block
copolym
cisdiamminedichloroplatinum
ii
cddp
poli
ethylen
oxid
blockpoli
lysin
peobpli
treat
lymph
node
metastasi
one
anim
treatment
wt
result
limit
tumour
growth
drain
lymph
node
prevent
system
metastasi
johnston
cowork
design
biodegrad
intrapleur
ipl
implant
paclitaxel
consist
gelatin
spong
impregn
poli
lactidecoglycolid
target
thorac
lymphat
rat
model
system
exhibit
lymphat
target
capabl
show
sustain
drug
releas
properti
kumanohoso
et
al
design
new
drug
deliveri
system
bleomycin
load
small
cylind
biodegrad
polylact
acid
target
lesion
system
show
significantli
higher
antitumour
effect
compar
bleomycin
solut
treatment
treat
lesion
new
biodegrad
colloid
particulatebas
nanocarri
system
design
target
thorac
lymphat
lymph
node
variou
nano
microparticl
charcoal
polystyren
poli
lactidecoglycolid
studi
lymphat
distribut
intrapleur
implant
rat
h
intrapleur
inject
lymphat
uptak
observ
kobayashi
et
al
utilis
dendrimerbas
contrast
agent
dynam
magnet
reson
lymphangiographi
gadolinium
gd
contain
dendrim
differ
size
molecular
structur
pamam
polyamidoamin
dab
diaminobutyl
use
contrast
agent
size
molecular
structur
play
great
role
distribut
pharmacokinet
dendrim
exampl
inject
intraven
compar
long
life
circulatori
system
minimum
leakag
vessel
wherea
clear
rapidli
system
circul
due
rapid
renal
clearanc
immedi
surviv
lymphat
circul
smallers
show
greater
accumul
retent
lymph
node
use
lymph
node
imag
use
mrlg
magnevist
evalu
control
imag
experi
reveal
reagent
abl
visualis
deep
lymphat
system
except
visualis
lymphat
vessel
lymph
node
use
respect
provid
good
contrast
node
connect
vessel
abl
visualis
lymph
node
clear
gdbase
dendrim
kobayashi
also
deliv
variou
gdpamam
dendrim
sentinel
lymph
node
evalu
visualis
node
dendrim
provid
excel
opacif
sentinel
lymph
node
abl
absorb
retain
lymphat
system
use
combin
mri
fluoresc
sentinel
node
clearli
observ
signifi
potenti
dendrim
platform
dual
imag
kobayashi
et
al
overcam
sensit
limit
depth
limit
individu
method
simultan
use
two
modal
radionuclid
optic
imag
make
use
dendrim
conjug
nearinfrar
nir
dye
radionuclid
probe
multimod
nanoprob
develop
radionuclid
multicolour
optic
lymphat
imag
later
kobayashi
also
propos
use
quantum
dot
label
cancer
cell
dendrimerbas
optic
agent
visualis
lymphat
drainag
identifi
sentinel
lymph
node
polylysin
dendrim
best
use
target
lymphat
system
lymph
node
carbon
nanotub
cnt
possess
variou
mechanochem
properti
like
high
surfac
area
mechan
strength
thermal
chemic
stabil
caus
versatil
carrier
drug
protein
radiolog
peptid
target
tumour
tissu
hydrophil
multiwal
carbon
nanotub
mwnt
coat
magnet
nanoparticl
mnmwnt
emerg
effect
deliveri
system
lymphat
target
follow
subcutan
inject
particl
left
footpad
spragu
dawley
rat
left
poplit
lymph
node
dy
black
mnmwnt
favour
absorb
lymphat
vessel
follow
transfer
lymph
node
uptak
seen
chief
intern
organ
liver
spleen
kidney
heart
lung
gemcitabin
load
particl
evalu
lymphat
deliveri
effici
display
maximum
concentr
gemcitabin
lymph
node
mcdevitt
et
al
synthesis
tumourtarget
watersolubl
cnt
construct
coval
attach
monoclon
antibodi
like
rituximab
lintuzumab
use
acid
dota
metal
ion
chelat
fluoresc
probe
fluorescein
cnt
dota
rituximab
explicitli
target
dissemin
human
lymphoma
vivo
trial
compar
control
cnt
dota
lintuzumab
rituximab
tsuchida
cowork
evalu
drug
deliveri
effici
waterdispers
carbon
nanohorn
nonsmal
cell
lung
cancer
model
polyethylen
glycol
peg
conjug
bound
oxidis
singlewal
carbon
nanohorn
oxswnh
inject
intratumour
mice
bear
human
nonsmal
cell
lung
cancer
caus
signific
retard
tumour
growth
histolog
analys
show
probabl
mean
interstiti
lymphat
fluid
transport
migrat
oxswnh
axillari
lymph
node
occur
major
site
breast
cancer
metastasi
near
tumour
shimada
et
al
describ
silica
particlebas
lymphat
drug
deliveri
system
bleomycin
compar
therapeut
efficaci
free
bleomycin
solut
transplant
tumour
model
anim
silica
particleadsorb
bleomycin
show
consider
inhibitori
effect
tumour
growth
lymph
node
metastasi
compar
free
bleomycin
solut
activ
carbon
particl
aclarubicin
use
adsorpt
sustain
releas
lymph
node
upon
subcutan
administr
fore
footpad
rat
particl
show
significantli
elev
distribut
aclarubicin
auxiliari
lymph
node
compar
aqueou
solut
drug
activ
carbon
particl
aclacinomycin
adriamycin
mitomycin
c
pepleomycin
also
use
anoth
group
adsorpt
higher
level
drug
concentr
maintain
new
dosag
form
solut
form
conjug
enhanc
cytotox
activ
anticanc
drug
conjug
antibodi
antibodi
conjug
cytostat
drug
calicheamicin
use
treatment
variou
lymphoma
includ
nonhodgkin
bcell
lymphoma
nhl
follicular
lymphoma
fl
diffus
larg
bcell
lymphoma
dlbcl
bcell
marker
express
surfac
membran
preblymphocyt
matur
blymphocyt
mab
rituximab
rituxan
potenti
antibodi
treatment
nonhodgkin
bcell
lymphoma
bnhl
rituximabconjug
calicheamicin
elev
antitumour
activ
rituximab
human
bcell
lymphoma
bcl
xenograft
preclin
model
blymphoid
lineagespecif
differenti
antigen
express
surfac
normal
malign
bcell
henc
antibodi
could
effect
deliv
chemotherapeut
drug
malign
bcell
also
antibodi
target
suit
trojan
hors
strategi
thu
antibodyconjug
therapeut
agent
bind
siglec
carri
effici
cell
lot
interest
seen
clinic
progress
conjug
antibodi
especi
inotuzumab
ozogamicin
express
malign
hodgkin
cell
classic
hodgkin
lymphoma
hl
anaplast
largecel
lymphoma
youn
bartlett
report
ongo
phase
doseescal
trial
relaps
refractori
hl
patient
seattl
genet
novel
e
conjug
stabl
blood
releas
conjug
upon
internalis
tumour
cell
huang
et
al
construct
anoth
conjug
examin
effect
murin
bcell
lymphoma
express
human
significantli
inhibit
tumour
growth
vivo
hybrid
system
use
combin
two
deliveri
form
effect
target
khatri
et
al
prepar
investig
vivo
efficaci
plasmid
dnaload
chitosan
nanoparticl
nasal
mucos
immunis
hepat
b
nanoparticl
prepar
coacerv
process
adher
nasal
gastrointestin
epithelia
easili
transport
nasalassoci
lymphoid
tissu
nalt
peyer
patch
gutassoci
lymphoid
tissu
galt
iga
induct
site
might
taken
cell
transport
across
mucos
boundari
therebi
transfect
immun
cell
within
nalt
galt
work
demonstr
target
three
peptid
contain
sequenc
bind
cell
marker
express
tumour
vasculatur
tumour
lymphat
test
abil
target
nitrilotriacet
acid
ditetradecylamin
contain
liposom
subcutan
tumour
significantli
potenti
antitumour
effect
seen
administr
doxorubicinload
liposom
engraft
hybrid
liposom
compos
polyoxyethylen
dodecyl
ether
prepar
sonic
show
remark
reduct
tumour
volum
model
mice
acut
lymphat
leukaemia
treat
intraven
without
drug
subcutan
inocul
human
cell
verifi
vivo
prolong
surviv
note
model
mice
treatment
without
drug
report
peptideconjug
pegyl
liposom
load
fluorescein
doxorubicin
prepar
target
treat
lymphat
metastat
tumour
vitro
cellular
uptak
vivo
nearinfrar
fluoresc
imag
result
confirm
liposom
increas
uptak
tumour
cell
metastat
lymph
node
anoth
studi
vitro
cellular
uptak
nanoparticl
four
time
nanoparticl
without
np
vivo
studi
eight
time
lymph
node
uptak
seen
metastasi
np
indic
promis
carrier
targetspecif
drug
deliveri
lymphat
metastat
tumour
current
surgeri
radiat
therapi
chemotherapi
princip
method
cancer
treatment
gene
therapi
may
act
synergist
addit
exampl
anoth
case
demonstr
replac
protein
gene
cancer
cell
line
enhanc
sensit
cell
adenovirusexpress
protein
cisplatin
cddp
result
greater
tumour
cell
death
later
son
huang
state
treatment
cddpresist
tumour
cell
cddp
increas
sensit
cell
transduct
dnacarri
liposom
also
chen
et
al
describ
improv
tumour
kill
herp
simplex
viru
thymidin
kinas
hsvtk
interleukin
il
express
combin
whole
greater
therapeut
effect
achiev
effect
combin
convent
cancer
treatment
gene
therapi
togeth
size
could
import
factor
defin
behaviour
particul
subcutan
inject
small
particl
diamet
less
nanometr
gener
exchang
blood
capillari
wherea
larger
particl
diamet
ten
nanometr
absorb
lymph
capillari
particl
size
hundr
nanometr
remain
trap
interstiti
space
long
time
christi
et
al
shown
relationship
colloid
size
eas
inject
site
drainag
use
model
polystyren
nanospher
subcutan
administr
rat
result
show
distribut
polystyren
nanospher
size
rang
nm
h
administr
recov
dose
retain
administr
site
particl
diamet
increas
drainag
becam
slower
propos
earlier
optimum
colloid
size
rang
lymphoscintigraph
agent
nm
size
less
import
colloid
administ
intraperiton
ip
within
nanometr
size
rang
drainag
caviti
initi
lymphat
henc
diffus
requir
interstiti
space
size
limit
open
junction
initi
lymphat
wall
barrier
uptak
periton
caviti
lymphat
number
particl
inject
site
decreas
rate
drainag
owe
increas
obstruct
diffus
interstiti
space
scientist
nottingham
univers
investig
effect
use
polystyren
nanospher
nm
follow
administr
rat
concentr
rang
nanospher
approxim
mgml
lower
lymphat
uptak
seen
increas
concentr
nanospher
inject
volum
due
slower
drainag
inject
site
inject
oili
vehicl
intramuscularli
rat
effect
inject
volum
studi
increas
volum
sesam
oil
acceler
oil
transport
lymphat
system
upon
sc
administr
volum
aqueou
polystyren
particl
suspens
investig
rang
surfac
charg
studi
done
utilis
liposom
colloid
carrier
surfac
charg
liposom
affect
lymphat
uptak
sc
ip
inject
site
neg
charg
liposom
show
faster
drainag
posit
liposom
ip
administr
patel
et
al
also
indic
liposom
localis
lymph
node
follow
particular
order
neg
posit
neutral
macromolecul
high
molecular
weight
decreas
abil
exchang
across
blood
capillari
lymphat
drainag
becom
rout
drainag
inject
site
show
linear
relationship
molecular
weight
macromolecul
proport
dose
absorb
lymphat
compound
absorb
lymphat
molecular
weight
rang
effect
molecular
weight
becom
neglig
target
carrier
lymphat
system
molecular
weight
colloid
carrier
gener
less
da
import
determin
phagocyt
respons
lymphat
uptak
lipophil
colloid
opsonin
gener
unit
lipophil
rather
hydrophil
surfac
henc
hydrophil
particl
show
reduc
phagocytosi
hydrophob
polystyren
nanospher
adsorb
hydrophil
block
copolym
show
drastic
reduct
phagocytosi
prior
iv
administr
case
polystyren
nanospher
diamet
peo
chain
poloxam
poloxamin
adsorb
onto
surfac
particl
describ
relationship
interstiti
inject
site
drainag
lymph
node
uptak
rat
uncoat
nanospher
diamet
show
reduc
drainag
inject
site
administ
dose
remain
h
adsorpt
block
copolym
enhanc
drainag
inject
site
level
remain
inject
site
may
littl
h
hydrophil
polym
poloxamin
uptak
nanospher
region
lymph
node
may
also
improv
adsorpt
block
copolym
intermedi
length
polyoxyethylen
poloxamin
polym
may
sequest
given
dose
lymph
node
h
coat
carrier
hydrophil
steric
stabilis
peg
layer
success
enhanc
lymphat
absorpt
reduc
specif
interact
particl
interstiti
surround
inhibit
format
larg
particl
structur
surfac
modif
liposom
peg
also
signific
effect
lymph
node
uptak
small
liposom
coat
peg
show
greatest
clearanc
sc
inject
site
small
pegcoat
liposom
remain
inject
site
h
larger
neutral
neg
charg
liposom
clearanc
remain
initi
sc
inject
site
howev
smaller
amount
larg
liposom
clear
inject
site
compens
better
retent
lymph
node
oussoren
et
al
report
amount
liposom
clear
inject
site
somewhat
greater
pegcoat
liposom
improv
clearanc
result
improv
lymph
node
retent
fraction
peg
liposom
retain
lymph
node
decreas
phillip
et
al
also
studi
slightli
improv
clearanc
pegcoat
liposom
sc
inject
site
porter
cowork
demonstr
pegyl
polyllysin
dendrim
result
better
absorpt
sc
inject
site
state
extent
lymphat
transport
may
improv
increas
size
pegyl
dendrim
complex
estim
lymphat
uptak
lymph
node
retent
properti
sever
gener
four
dendrim
coat
peg
sulphon
subcutan
administr
rat
surfac
modif
studi
three
type
peg
molecular
weight
da
taken
dendrim
show
rapid
complet
absorpt
blood
inject
subcutan
total
given
dose
found
pool
thorac
lymph
h
wherea
dendrim
show
lesser
absorpt
higher
amount
recov
lymphat
h
howev
benzen
sulphonatecap
dendrim
well
absorb
either
blood
lymph
follow
subcutan
inject
carrier
cap
nonspecif
human
antibodi
ligand
show
greater
lymphat
uptak
lymph
node
retent
compar
uncoat
one
sc
site
liposom
coat
antibodi
igg
shown
increas
lymph
node
localis
liposom
inject
dose
h
level
decreas
h
studi
liposom
contain
posit
charg
lipid
approxim
time
lymph
node
localis
inject
dose
liposom
contain
neutral
neg
charg
lipid
inject
dose
attach
mannos
surfac
liposom
increas
lymph
node
uptak
threefold
compar
control
liposom
anoth
studi
demonstr
hbsag
entrap
dri
liposom
surfac
modifi
galactos
pharmacokinet
studi
rat
show
galactosyl
liposom
deliv
higher
amount
hbsag
region
lymph
node
ungalactosyl
formul
lectin
anoth
ligand
attach
carrier
improv
target
intestin
lymphat
bovin
serum
albumin
contain
acid
phosphatas
model
protein
polystyren
microspher
conjug
mous
mcellspecif
ulex
europaeu
lectin
ex
vivo
result
show
favour
bind
lectinconjug
microspher
follicleassoci
epithelium
final
result
indic
coupl
ligand
lectin
specif
cell
follicleassoci
epithelium
improv
target
encapsul
candid
antigen
deliveri
peyer
patch
intestin
better
oral
deliveri
improv
carrier
retent
lymph
node
new
method
increas
lymphat
uptak
subcutan
inject
liposom
utilis
highaffin
ligand
biotin
avidin
biotin
natur
occur
cofactor
avidin
protein
deriv
egg
avidin
biotin
extrem
high
affin
instanc
upon
inject
avidin
biotin
liposom
move
lymphat
vessel
biotin
liposom
migrat
lymphat
vessel
meet
avidin
result
aggreg
becom
trap
lymph
node
biotin
liposomeavidin
system
promis
potenti
therapeut
agent
deliveri
lymph
node
appli
sc
target
lymph
node
also
intracavitari
lymph
node
target
differ
ligand
applic
lymphat
target
repres
tabl
lymphat
potenti
play
major
role
anticanc
treatment
lymphat
spread
recognis
preced
haematolog
spread
mani
cancer
includ
melanoma
breast
colon
lung
prostat
cancer
current
focu
develop
drug
carrier
localis
chemotherapi
lymphat
system
thu
improv
treatment
localis
diseas
minimis
exposur
healthi
organ
cytotox
drug
deliveri
novel
carrier
lymph
node
therapeut
purpos
much
promis
give
import
lymphat
rout
metastasi
deliveri
system
may
great
potenti
target
deliveri
variou
therapeut
agent
tumour
metastat
lymph
node
variou
deliveri
system
discuss
colloid
carrier
especi
liposom
carrier
choic
date
purpos
review
provid
improv
effect
lymphotrop
system
satisfactori
qualiti
clinic
use
establish
prepar
method
applic
industri
product
surfaceengin
lymphotrop
system
may
prove
effect
carrier
antihiv
anticanc
oral
vaccin
deliveri
near
futur
